Collegium Pharmaceutical, Inc.
COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to requirā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$35.39
Price-1.64%
-$0.59
1Y
Price
Market Cap
$1.148b
Small
Price/Earnings 3y Avg5y Avg
4.6x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+58.1%
EBITDA Margin+15.1%
Net Profit Margin+37.4%
Free Cash Flow Margin+58.1%
EBITDA Margin+15.1%
Net Profit Margin+37.4%
Free Cash Flow MarginRevenue
$796.330m
+19.9%
1y CAGR+17.8%
3y CAGR+30.3%
5y CAGREarnings
$74.949m
-15.5%
1y CAGR+106.9%
3y CAGR+46.5%
5y CAGREPS
$2.04
-14.0%
1y CAGR+101.5%
3y CAGR+41.2%
5y CAGRBook Value
$312.422m
$1.652b
Assets$1.340b
Liabilities$808.056m
DebtDebt to Assets
48.9%
2.4x
Debt to EBITDAFree Cash Flow
$329.826m
+42.3%
1y CAGR+46.7%
3y CAGR+40.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company